Companies › Procter and Gamble
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 4; Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Test Stannous Fluoride Dentifrice Stannous fluoride (0.454%) dentifrice for anti-gingivitis and plaque reduction | SNF2 | Phase 4 | Gingivitis | – |
| Sodium Monofluorophosphate Dentifrice | – | Phase 1 | Gingivitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06962956 | Test Stannous Fluoride Dentifrice | Phase 1 | Gingivitis | Gastroenterology | Oct 2025 |
| NCT06962956 | Sodium Monofluorophosphate Dentifrice | Phase 1 | Gingivitis | Gastroenterology | Oct 2025 |
| NCT07158112 | Test Stannous Fluoride Dentifrice | Phase 4 | Gingivitis | Gastroenterology | Dec 2025 |
Cash of $15.4bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
–
Colgate Palmolive Healthgen Biotechnology NorthSea Therapeutics TRYP Therapeutics Green Cross Wellbeing
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.